Loading
Neutropenia and Cancer Infections / Ovarian Cancer Diagnosis and Treatment · Journal article
Pharmacological Reports · August 12, 2026
Early or partial results. Treat as a signal, not a conclusion.
This retrospective study identifies several clinical parameters from prior platinum chemotherapy that associate with hematological toxicity during subsequent PARP inhibitor maintenance in ovarian cancer patients. The authors themselves classify the findings as hypothesis-generating and explicitly state they require external validation before clinical implementation, limiting immediate applicability.
Retrospective cohort study. Patients with high-grade serous ovarian cancer who received first-line platinum chemotherapy followed by PARP inhibitor maintenance therapy (niraparib or olaparib).. Intervention: PARP inhibitor maintenance therapy (niraparib n=49 or olaparib n=81). n = 130.
Higher minimal hemoglobin during chemotherapy independently associated with higher minimal platelet count during niraparib (β = 67.41, 95% CI 16.39–118.43, p = 0.011) Higher minimal neutrophil count during chemotherapy independently associated with grade 3–4 thrombocytopenia during niraparib (OR = 4.51, 95% CI 1.47–17.96, p = 0.015) Lower minimal platelet count during chemotherapy independently associated with grade 3–4 thrombocytopenia during niraparib (OR = 0.975, 95% CI 0.958–0.989, p = 0.001)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should regard these associations as exploratory observations requiring validation in an independent prospective cohort before modifying monitoring or dosing strategies. The drug-specific toxicity patterns (thrombocytopenia with niraparib, anemia with olaparib) may inform risk stratification, but clinical thresholds and actionable cutoffs are not established.
Retrospective single-centre analysis identifying associations between chemotherapy-induced parameters and PARP inhibitor toxicity, but lacks prospective validation, external cohort confirmation, and actionable clinical thresholds for practice change.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should regard these associations as exploratory observations requiring validation in an independent prospective cohort before modifying monitoring or dosing strategies. The drug-specific toxicity patterns (thrombocytopenia with niraparib, anemia with olaparib) may inform risk stratification, but clinical thresholds and actionable cutoffs are not established.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is a standard treatment in selected ovarian cancer patients. However, hematological toxicity remains a clinical problem. The study aimed to identify predictors of early hematologic toxicity during PARP inhibitor maintenance therapy in high-grade serous ovarian cancer. We retrospectively analyzed 130 patients receiving PARP inhibitors (niraparib, 49; olaparib, 81). Blood counts from first-line platinum chemotherapy and from the first 3 months of PARP inhibitor therapy were assessed. Adverse events were graded using the Common Terminology Criteria for Adverse Events v5.0. Weekly changes and minimal values for neutrophils, hemoglobin, and platelets were calculated (excluding post-intervention values). Thrombocytopenia was mainly related to niraparib treatment, and anemia was mainly related to olaparib treatment. During niraparib therapy, higher human epididymis protein 4 (He4) at diagnosis correlated with greater platelet decline and lower platelet nadir. In multivariable linear regression, higher body weight (β = 1.86, 95% CI 0.05 to 3.67, p = 0.044) and higher minimal hemoglobin during chemotherapy (β = 67.41, 95% CI 16.39 to 118.43, p = 0.011) were independently associated with higher minimal platelet count during niraparib treatment. In multivariable logistic regression, higher minimal neutrophil count during chemotherapy (OR = 4.51, 95% CI 1.47 to 17.96, p = 0.015) and lower minimal platelet count during chemotherapy (OR = 0.975, 95% CI 0.958 to 0.989, p = 0.001) were independently associated with grade 3 or 4 thrombocytopenia during niraparib treatment. In the olaparib cohort, lower minimal neutrophil count during chemotherapy (β = -0.414, 95% CI -0.755 to -0.074, p = 0.018) and higher hemoglobin concentration at qualification for PARP inhibitor therapy (β = 0.533, 95% CI 0.042 to 1.024, p = 0.034) were independently associated with higher minimal hemoglobin during treatment. Early, severe cytopenias during PARP inhibitor therapy can be predicted using clinical data. Platinum-related side effects and parameters for disease diagnosis and eligibility for PARP inhibitor therapy identify high-risk patients, supporting risk-adapted monitoring and proactive dose optimization. These findings should be considered hypothesis-generating and require external validation before implementation in clinical decision-making. Not applicable
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.